Canagliflozin and cardiovascular and renal events in type 2 diabetes

By R. Guthrie. Postgraduate medicine, 2018

2,738 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/f5ccd1e72a2d033aa4ee35d00f9e9c8abea27163

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Dandan Zhang
2. Ziwei Cui
3. Rui-Juan Guo
4. Xiao-Fu Huang
5. Mei Han
6. Peng Kong

Citations in the corpus

• Inflammation and atherosclerosis: signaling pathways and therapeutic intervention (2022, background): “In two trials involving T2DM patients at high risk of cardiovascular disease, patients receiving canagliflozin had a lower risk for cardiovascular events than those receiving placebo, but a higher risk of amputation.(337)”